News & CommentBioethics

Panel Approves Gene Trial for ‘Normals’

See allHide authors and affiliations

Science  14 Mar 1997:
Vol. 275, Issue 5306, pp. 1561
DOI: 10.1126/science.275.5306.1561

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

The panel that for more than a decade has vetted safety and ethical issues in U.S. human gene-therapy research—the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH)—ended its role as gatekeeper with a bang last week, grilling a researcher who had proposed a clinical trial that would inject engineered genes for the first time into normal, healthy volunteers. RAC's final act as enforcer also gave a preview of how it might handle the new role that NIH director Harold Varmus has envisioned for the committee—as a forum for debates on ethical issues.